Japan’s latest five-year health and medical R&D strategy offers a timely case study for Australia’s own life sciences ecosystem, particularly as we continue to confront familiar challenges around clinical trial competitiveness, translational capability, sovereign capability and access to innovation.

Approved in early 2025, Japan’s “Third Term of the Health and Medical Strategy” signals a significant national repositioning. It is a coordinated effort to strengthen research competitiveness, address drug lag and drug loss, and build a more effective clinical and regulatory ecosystem. For Australian professionals across regulatory affairs, clinical research, medical affairs, policy and commercialisation, there are important lessons in both ambition and execution.

A strategic shift from research to end-to-end ecosystem performance

What stands out most is Japan’s recognition that biomedical innovation is not simply about discovery. It is about the full pathway from early science through translation, clinical development, regulation and patient access.

The Third Strategy introduces a far more integrated framework than its predecessor, including a stronger emphasis on infectious diseases, translational science and clinical acceleration. In practical terms, this means Japan is actively investing not just in basic research capability, but in the systems required to move therapies efficiently from concept to clinic.

For Australia, this should resonate deeply. Australia has long been recognised as a strong destination for early-phase clinical trials, supported by quality investigators, an attractive R&D tax incentive framework and globally respected ethics processes. Yet we also face persistent challenges:

• fragmented governance across institutions

• site start-up variability

• workforce capability gaps

• translation bottlenecks

• global competition for sponsored trials

The broader message is clear: nations that succeed in life sciences increasingly compete on ecosystem efficiency, not just scientific excellence.

Clinical trials as national infrastructure

Perhaps the most relevant aspect for ARCS members is Japan’s explicit positioning of clinical trials as strategic national infrastructure.

Japan identified decentralised ethics and IRB systems as barriers to speed and competitiveness and has now set a target that more than 80% of multicentre trials will move to a single-IRB model over the coming years. This is a major structural reform aimed at reducing duplication, accelerating activation and improving international attractiveness.

For Australia, where conversations continue around the National One Stop Shop (NOSS), public site governance, ethics harmonisation and start-up reform, this reinforces an important point: reducing friction matters.

Clinical trial capability is no longer simply an operational issue. It is a strategic economic lever.

This is particularly relevant as Australia seeks to strengthen:

• international collaborative trial attractiveness

• medtech and biotech commercialisation

• advanced therapeutics

• public and private site sustainability

At ARCS, this aligns directly with ongoing discussions around professionalism, capability frameworks and building a stronger, more connected clinical ecosystem.

Infectious disease, sovereign capability and avoiding “panic and neglect”

Japan’s strategy also explicitly addresses what it describes as “Panic and Neglect” which refers to the cycle of crisis-driven urgency followed by complacency once immediate threats fade.

This concept should feel familiar.

COVID-19 highlighted both the strengths and vulnerabilities of health systems globally, including Australia’s dependence on global supply chains, vaccine access pathways and domestic manufacturing limitations. Japan’s response is to institutionalise infectious disease preparedness through vaccines, therapeutics and diagnostics as enduring strategic priorities rather than episodic reactions.

Australia’s own policy landscape increasingly reflects similar priorities through medical manufacturing, sovereign capability and advanced therapeutics investment. The challenge will be maintaining momentum beyond immediate political cycles.

For ARCS members, this reinforces the growing importance of cross-functional capability where regulatory, manufacturing, clinical and policy professionals all play roles in resilience.

International collaboration, AI and the next competitive frontier

Japan’s new One-Stop Consultation Service for international collaborative trials is particularly notable because it targets global biotech and start-up engagement. It is effectively a market-facing strategy to attract innovation into Japan by simplifying navigation.

This raises a strategic question for Australia:

Are we sufficiently easy to navigate for international innovators?

Australia’s advantages are real, but our global competitiveness will increasingly depend on:

• clearer pathways

• workforce sophistication

• integrated regulatory and trial systems

• AI-enabled efficiency

Japan’s explicit commitment to AI across the clinical and regulatory continuum is also significant. While AI hype is abundant, the more meaningful shift is operational: AI as an infrastructure enabler for trial design, site management, regulatory review and evidence generation.

This is where ARCS professionals are already seeing transformation across pharmacovigilance, regulatory affairs, education and knowledge systems.

What this means for Australia’s life sciences workforce

The strongest takeaway may be this: strategy alone is insufficient without workforce capability.

Japan’s roadmap is backed by measurable targets, budgets and governance mechanisms. It recognises that competitiveness depends on coordinated systems and skilled professionals who can execute across disciplines.

For Australia, and for ARCS as a professional body, this underscores why advancing professionalism matters.

The future will increasingly reward professionals who can bridge:

• science and strategy

• clinical and commercial

• regulation and innovation

• local systems and global opportunity

  
  

Final thought

Japan’s Third Strategy is ultimately a reminder that life sciences leadership is built deliberately.

For Australia, the opportunity is substantial. We have world-class science, strong clinical capability and growing ambition. But if we are to remain globally competitive, our focus must extend beyond isolated strengths to whole-of-ecosystem excellence.

In other words, the next phase is not simply about participating in global innovation.

It is about shaping the systems, workforce and professionalism that allow Australia to lead.